Anemia of inflammation (AI), a normochromic, normocytic anemia, associated with abnormal iron
utilization, erythropoietin hyporesponsiveness, and decreased red blood cells (RBC) survival
is a very common problem in hospitalized patients for acute inflammatory diseases and
develops within few days from the onset of illness. Deleterious effects of anemia include
increased risk of cardiac related morbidity and mortality in critically ill and older
Anemia is mediated by hepcidin, the 25-amino acid polypeptide hormone that is central to iron
Several studies have been performed on pathophysiology of AI in patients affected by chronic
diseases but few explore iron metabolism in humans with acute inflammation.
The aim is to develop effective new strategies to detect and manage AI in the setting of
acutely ill patients, based on the understanding of iron balance underlying this disorder.